TrialPLoS pathogens2020

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.

Yves Lévy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.